Ripple Therapeutics Presents at ARVO 2024
Ocular tolerability and IOP-lowering evaluation of the RTC-620 intracameral implant in normotensive beagle dogs
Ike Iqbal K Ahmed, Kyle Battiston, Shadi Taghavi, Mahta Massoud, Eamon Kelly, Hans Fischer, Dimitra Louka, Matthew Statham, Jonathan Day, Adam Daley, Ian Parrag, Wendy Naimark
IBE-814 IVT Implants reduce treatment burden in subjects with DME and RVO due to sustained-release of dexamethasone: An analysis of the First-in-Human Phase 2 RIPPLE-1 trial
Kelli Wootton, Gillian Mackey, Madeline Simpson, Joseph Reiz, Wendy Naimark
Efficacy and safety of a low dose dexamethasone implant for diabetic macular edema and retinal vein occlusion: Results of the First-In-Human Phase 2 RIPPLE-1 trial
Hemal Mehta, Kelli Wootton, Madeline Simpson, Gillian Mackey, Wendy Naimark
Chronic ocular tolerability and pharmacodynamics of the RTC-1119 intracameral implant in normotensive beagle dogs
Kyle Battiston, Shadi Taghavi, Hans Fischer, Matthew Statham, Jonathan Day, Emily Baldwin, Adam Daley, Ian Parrag, Wendy Naimark
Canadian Business Wendy Naimark, October 20, 2025 https://canadianbusiness.com/sponsored/why-a-homegrown-biotech-sector-matters/ Canada has the talent and innovation to lead in biotech, but without stronger investment, breakthroughs risk leaving our borders.
Ripple is featured (page 48) in LSO’s Success Stories publication, celebrating the groundbreaking work and inspiring contributions of Ontario’s life sciences organizations. View Presentation
